HETERO LABS LIMITED
Location
Telangana
Founded
1989-03-10
Website
Risk Signals
265 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about HETERO LABS LIMITED
Live alerts from global media, monitored by Business Radar
2024-09-03 (vccircle.com)
Searchlight: Hetero Health rebounds after post-COVID crash on manufacturing boost
Hetero Healthcare Ltd, which is a part of one of the major pharmaceutical groups in India Hetero group, witnessed a ...
Read more
2023-01-17 (prnewswire.com)
Hetero's 'Nirmacom' is world's first generic version of COVID-19 oral drug 'PAXLOVID' to receive WHO Prequalification
/PRNewswire/ -- Hetero, India's leading pharmaceutical company with the widest global reach, today announced the receipt of World Health Organization...
Read more
2022-12-27 (reuters.com)
India-based Hetero's Paxlovid generic gets WHO backing
India's Hetero said on Tuesday that its generic version of Paxlovid, an antiviral treatment for COVID-19 developed by Pfizer Inc , was added to the World Health Organization's prequalification list, which serves as a benchmark for procurement of medicines by developing countries.
Read more
2022-01-06 (thewire.in)
The Zydus Cadila Remdesivir Fiasco Wasn’t an Isolated Incident – The Wire Science
Discussions with regulators and procurers suggest these agencies may have ignored many similar incidents during India's COVID-19 epidemic.
Read more
2021-08-23 (drugstorenews.com)
Q&A: Camber’s Ostaficiuk discusses generic firm’s growing portfolio
DSN talks to Camber Pharmaceuticals president Kon Ostaficiuk about the company's pandemic efforts and the recent additions to its pharmaceutical and store-brand OTC offerings.
Read more
2021-07-09 (reuters.com)
India's Hetero seeks emergency use nod for Merck's COVID-19 drug
India's Hetero Labs said on Friday it sought emergency use nod from the local regulator for Merck's COVID-19 drug molnupiravir, after interim data from a late-stage trial showed it helped reduce hospitalisations and speed up recovery in mild cases.
Read more
2021-04-27 (businesstoday.in)
Hetero-Merck alliance seeks emergency use nod for anti-COVID drug Molnupiravir in India
Under this licensing deal, Hetero will be allowed to sell Molnupiravir in India and in other low-and middle-income countries (LMICs), following the approvals for emergency use authorisation by local regulatory agencies
Read more
2020-10-08 (businesstoday.in)
Hetero to develop injection form of COVID-19 drug Favipiravir
Favipiravir which was originally designed to cure influenza is now used in the treatment of coronavirus patients.
Read more
2020-07-29 (expresspharma.in)
Hetero launches Favivir to treat mild to moderate Covid-19
Favivir, priced at Rs 59 per tablet, will be available at all retail medical outlets and hospital pharmacies across the country but will be sold only on prescription
Read more
2020-06-21 (reuters.com)
India gives Hetero Labs and Cipla approval to make Gilead's COVID-19 drug
India's drug regulator has given Hetero Labs and Cipla Ltd <CIPL.NS> the green light to manufacture and market their generic version of Gilead Sciences Inc's <GILD.O> experimental COVID-19 treatment remdesivir, the Indian pharmaceutical companies said on Sunday.
Read more
2020-06-21 (expresspharma.in)
Hetero announces launch of generic remdesivir ‘COVIFOR’ for COVID-19 treatment
COVIFOR will be available in 100 mg vial (injectable) which has to be administered intravenously in a hospital setting under the supervision of a healthcare practitioner
Read more
2020-06-21 (businesstoday.in)
Coronavirus drug update: Cipla, Hetero to launch Remdesivir at Rs 3,000-6,000
Cipla plans to launch the drug in a couple of days, while Hetero's drug is expected to hit the market in a week
Read more